Intracapsular metformin bioactivity and its role in posterior capsule opacification

Area of Science:

• Ophthalmology
• Pharmacology
• Cell Biology

Background:

• Posterior capsule opacification (PCO) is a common complication after cataract surgery, driven by residual lens epithelial cell (LEC) proliferation.
• Metformin, an antidiabetic drug, possesses antifibrotic properties that may inhibit LECs.

Purpose of the Study:

• To determine if systemically administered metformin reaches the human lens capsule.
• To assess metformin's ability to inhibit LEC proliferation at physiologically relevant concentrations.

Main Methods:

• Quantified metformin in serum and lens capsule tissue from diabetic patients undergoing cataract surgery using LC-MS/MS.
• Cultured human anterior lens capsules with or without metformin and monitored LEC proliferation via live-cell imaging.

Main Results:

• Metformin was detected in both serum and lens capsule specimens, with significant correlation between the two.
• In vitro, metformin significantly reduced LEC proliferation compared to controls (p<0.001).

Conclusions:

• Systemic metformin effectively reaches the human lens capsule.
• Metformin suppresses LEC proliferation in vitro at clinically relevant concentrations, suggesting its potential as a PCO preventative agent.